Cure My Disease

Don't miss your cure!

 Log in / Sign up

New smart bomb for liver cancer: radiation drug targets tumors only

NCT ID NCT06764316

Recruiting now Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 6 times

Summary

This early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, some receiving the drug alone and others in combination with other treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BAY 3547926 (a drug that delivers radiation directly to cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for advanced liver cancer that targets cancer cells while sparing healthy tissue.
What could go wrong
This is a very early Phase 1 trial, so the drug may not be safe or effective. Only 148 people will take part, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

  • Dothan

    RECRUITING

    Dothan, Alabama, 36303, United States

  • Duarte

    RECRUITING

    Duarte, California, 91010, United States

  • Edegem

    RECRUITING

    Edegem, Antwerp, 2650, Belgium

  • Glasgow

    RECRUITING

    Glasgow, Scotland, G12 0YN, United Kingdom

  • Kortrijk

    RECRUITING

    Kortrijk, West Flanders, 8500, Belgium

  • L'Hospitalet de Llobregat

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Leuven

    RECRUITING

    Leuven, Flemish Brabant, 3000, Belgium

  • London

    RECRUITING

    London, Greater London, NW3 2QG, United Kingdom

  • London

    RECRUITING

    London, Greater London, W12 0HS, United Kingdom

  • Madrid

    RECRUITING

    Madrid, Madrid, 28050, Spain

  • Montpellier

    RECRUITING

    Montpellier, Occitanie, 34298, France

  • Montreal

    RECRUITING

    Montreal, Quebec, H2X 0C1, Canada

  • Montreal

    RECRUITING

    Montreal, Quebec, H4A 3J1, Canada

  • Pamplona

    RECRUITING

    Pamplona, Spain

  • Sherbrooke

    RECRUITING

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Sutton

    RECRUITING

    Sutton, Surrey, SM2 5PT, United Kingdom

  • Tampere

    RECRUITING

    Tampere, Pirkanmaa, 33520, Finland

  • Toronto

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

  • Turku

    RECRUITING

    Turku, Southwest Finland, 20540, Finland

  • Xuhui District

    RECRUITING

    Xuhui, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.